Wire · opportunities
AACR Report Highlights Rapid Expansion of Molecularly Targeted Cancer Therapies
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 16 September 2026 · Fusion42 review
The AACR 2026 report highlights the FDA approval of 10 new molecularly targeted cancer therapies and expanded indications for two others, improving precision treatment across multiple cancer types in the United States. Companion diagnostics are increasingly critical for identifying suitable patients, although access disparities and treatment resistance remain major challenges.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You face a sharp rise in FDA-approved targeted cancer treatments needing companion diagnostic support. Get ahead by integrating genetic testing to match therapies and prepare for patient demand despite uneven access.
◆ Coverage
1 source · 16 Sep 2026
◆ Related on Wire
◆ Topics